drug
monlunabant
Phase 2updated 5mo agoby Inversago Pharma Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying monlunabant
News(3)
- Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, SanofiCorbus Pharmaceuticals’ phase 1b obesity trial has generated evidence that its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The…fiercebiotech · 16d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 1mo ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that